Yes, but saving that cash will go on the expense of clinical progress: if pivotal mono is to start, GvHD, TNBC to ramp up with multiple trial sites, about 4m or so cash per month will still be needed.

Bottom line is a deal is still needed in order to progress as planned (unless SP will be substantially higher after BLA submission, which remains to be seen). 4m per month to go full-speed on the trials plus at least 25m for a soft-launch in case of going it alone.